Wegovy HD (Semaglutide 7.2 mg): What the New Higher Dose Means

A plain-language look at the FDA-approved 7.2 mg dose: who it is for, what the STEP UP trial showed, and the higher-dose side effect worth knowing about.

If you have been on Wegovy for a while and your weight has settled into a plateau, you may have heard about a new option and wondered whether it applies to you. In March 2026 the FDA approved Wegovy HD, a once-weekly semaglutide injection at 7.2 mg. It is the highest semaglutide dose cleared for weight management so far, and the headlines have been loud. Here is the calmer version: what it is, who it is actually for, what the trial showed, and the one side effect that shows up more at this dose.

What Wegovy HD actually is

Wegovy HD is brand-name semaglutide at a 7.2 mg once-weekly dose, approved by the FDA on March 19, 2026, for chronic weight management in adults. It is meant to be used the way the lower doses are: alongside a reduced-calorie diet and more physical activity, not instead of them. Novo Nordisk expected to launch it in the United States as a single-dose pen in April 2026.

One detail worth noting for the policy-minded: the approval came through the FDA Commissioner's National Priority Voucher pilot, a newer program meant to speed review of selected products. Wegovy HD was the fourth product cleared under it, with the decision granted roughly 54 days after filing. That is fast by historical standards, and it does not change the fact that the dose was studied in a large phase 3 program before approval.

Who it is for, and who it is not

This is the part most people skip, and it matters most. Wegovy HD is not a starting dose. The label is specific: it is for adults who have already tolerated the 2.4 mg dose for at least four weeks and for whom additional weight reduction is clinically indicated. In plain terms, it is a step up for people who have done well enough on standard Wegovy to stay on it, are handling it, and still have meaningful weight to lose.

It is not a signal that everyone on 2.4 mg should move up, and it is not a case of more always being better. Plenty of people reach a good, stable result on the standard dose and have no reason to change. If you are new to semaglutide, you do not start here; you build up gradually, and our post on the semaglutide dosing schedule walks through why titration exists in the first place. Whether HD is a fit is a conversation for your prescriber, not a box you check because a higher number exists.

What the STEP UP trial showed

The main evidence comes from a phase 3b trial called STEP UP. It enrolled 1,407 adults with obesity (BMI 30 or higher) and without diabetes, and ran for 72 weeks. On average, people on semaglutide 7.2 mg lost about 20.7% of their body weight, compared with roughly 17.5% on the standard 2.4 mg dose and much less on placebo. About one in three participants (near 31%) reached at least 25% weight loss, and about 89% reached at least 5%.

A companion trial in adults who had both obesity and type 2 diabetes, STEP UP T2D, showed a mean loss of about 14.1%. That smaller number is expected; weight loss tends to run lower in people with diabetes across GLP-1 studies in general, not just this one.

Two honest caveats. First, these are averages from a controlled trial. A 20.7% mean does not mean you will lose 20.7%; some people lose more, some less, and real life includes missed doses, plateaus, and everything else. If you want a grounded sense of the range, we cover that in how much weight you can lose on a GLP-1. Second, the jump from about 17.5% to about 20.7% is real but modest. It is a few extra percentage points on average, not a different category of result. For the original benchmark these numbers are measured against, our breakdown of the STEP 1 results is a useful reference point.

The side effect that shows up more at this dose

Here is where the higher dose earns its own conversation. In STEP UP, a side effect called dysesthesia appeared far more often at 7.2 mg than at lower doses. Dysesthesia means an altered skin sensation: tingling, numbness, or a burning feeling on the skin. It was reported in about 22% of people on 7.2 mg, versus about 6% on 2.4 mg and about 0.3% on placebo. Most reported cases were mild to moderate, but the pattern is clear, and it is roughly what sets this dose apart from the standard one on the safety side.

Beyond that, the side effects looked like the rest of the GLP-1 class and like prior semaglutide experience: mostly gastrointestinal, most commonly nausea, vomiting, constipation, abdominal pain, and fatigue, usually mild to moderate. None of this is a reason to avoid the dose or to chase it. It is a reason to weigh the extra few points of average weight loss against a meaningfully higher chance of that skin-sensation symptom, with the person who prescribes for you.

How HD differs from staying on 2.4 mg

If 2.4 mg is your maintenance dose and it is working, staying put is a perfectly reasonable plan. HD is not an upgrade everyone graduates to. The practical differences are three: a somewhat larger average weight loss, a higher rate of the dysesthesia signal above, and a product that, at least at launch, comes as a single-dose pen. Everything else carries over. The weekly injection, the diet-and-activity foundation, and the general GLP-1 side-effect profile are the same.

Wegovy HD is not the same as compounded semaglutide

This gets muddled a lot, so let us be plain. Wegovy HD is an FDA-approved, brand-name finished drug from Novo Nordisk, studied at a specific dose. Compounded semaglutide is a different thing: it is prepared by a licensed compounding pharmacy, it is not FDA-approved, and it is not brand-identical. Results vary. A 7.2 mg number from a Wegovy trial does not transfer to a compounded product, and no compounded formulation should be labeled "Wegovy HD." They are separate categories, and honest clinics keep them separate. If you are weighing brand options in general, Ozempic vs Wegovy lays out how the same molecule shows up under different labels and approvals.

What the approval does not change

A couple of things get over-read when a new dose lands. Wegovy's cardiovascular benefit, the finding that it can lower the risk of certain heart events in specific patients, rests on the 2.4 mg dose that was studied for it. The HD approval is based on weight, not on a new heart-outcomes result at 7.2 mg, so do not assume the higher dose buys extra cardiovascular protection. And nothing here is dosing advice. Do not start, stop, raise, or lower any prescription on your own. The label's own gate, tolerating 2.4 mg for at least four weeks first, exists precisely because these decisions belong with a licensed prescriber who knows your history.

The bottom line

Wegovy HD is a real, FDA-approved, higher-dose option for a specific group: adults who have tolerated standard Wegovy, are still carrying meaningful weight, and want to go further under medical supervision. On average it delivers a few more percentage points of weight loss, at the cost of a clearly higher rate of altered skin sensation. It is not a starting dose, not for everyone, and not the same as anything compounded. If you are on semaglutide now and wondering whether this fits, that is exactly the kind of question worth bringing to a visit, where someone can look at your response so far, your tolerance, and your goals before anything changes.

Wegovy and Ozempic are registered trademarks of Novo Nordisk. New Hope Weight Loss and Wellness is not affiliated with, endorsed by, or sponsored by Novo Nordisk. This article is educational and is not medical advice; dosing decisions belong to your licensed prescriber.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.